Characterization of the hypoglycemic drug glibenclamide;Caracterização do fármaco hipoglicemiante glibenclamida

Revista Brasileira de Ciencias Farmaceuticas/Brazilian Journal of Pharmaceutical Sciences

Volumn 44, Issue 1, 2008, Pages 61-73

  Nery, Christiane Gino Colu ^a   Pires, Maria Arlete Da Silva ^a   Pianetti, Gerson Antônio ^a   Vianna Soares, Cristina Duarte ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Glibenclamide characterization; Hypoglycemic agent

Indexed keywords

GLIBENCLAMIDE;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG RELEASE; DRUG SOLUBILITY; LASER DIFFRACTION; TABLET COMPRESSION; TABLET DISINTEGRATION TIME; TABLET FORMULATION; THERMOGRAVIMETRY; ULTRAVIOLET SPECTROSCOPY; X RAY ANALYSIS;

EID: 46449091408     PISSN: 15169332     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-93322008000100008     Document Type: Article

References (29)

1. AHFS drug information 2000. Bethesda: American Society of Health System Pharmacist, 2000, p.2850-2856.
2. BABU, R.J.; PANDIT, J.K. Enhancement of dissolution rate and hypoglycemic activity of glibenclamide with b-cyclodextrin. S.T.P. Pharma Sci., v.5, p.196-201, 1995.
3. BRASIL. Ministério da Saúde. Anvisa aprova primeiros genéricos para tratamento da diabetes. Brasília, 2001a. Disponível em: 〈http://portalweb02.saude.gov.br/saude/aplicacoes/ noticias/noticias_detalhe.cfm?co_seq_noticia=427〉. Acesso em: 19 set. 2002.
4. BRASIL. Ministério da Saúde. Durante a Campanha Nacional de Detecção de Diabetes foram examinados mais de 20 milhões de pessoas. Brasília, 2001b. Disponível em: 〈http://portalweb02.saude.gov.br/saude/aplicacoes/noticias/ noticias_detalhe.cfm?co_seq_noticia=415〉. Acesso em: 19 set. 2002
5. BRASIL. Ministério da Saúde. Saúde aprova genérico para tratamento de gota e diabetes. Brasília, 2001b. Disponível em: 〈http://portalweb02.saude.gov.br/saude/aplicacoes/ noticias/noticias_detalhe.cfm?co_seq_noticia=458〉. Acesso em: 20 set. 2002.
6. BRITISH pharmacopeia. London: Her Majesty's Stationery Office, 2003a. v.1, p.871-872.
7. BRITISH pharmacopeia. London: Her Majesty's Stationery Office, 2003b. v.3, p.2358-2359.
8. BRUNAUER, S.; EMMETT, P.H.; TELLER, E. Adsorption of gases in multimolecular layers. J. Am. Chem. Soc. v.60, p.309-319, 1938.
9. CLARKE, E.G.C., (Org.). Isolation and identification of drugs. 2.ed. London: Pharmaceutical Press, 1986. p.638-639.
10. CLAS, S-D; DALTON, C.R; HANCOCK, B.C. Differential scanning calorimetry: application in drug development Pharm. Sci. Technol. Today, v.2, p.311-320, 1999.
11. EUROPEAN pharmacopeia. Strasbourg: European Department for Quality of Medicines, 1997. p.898.
12. FARMACOPEA de los Estados Unidos Mexicanos. 7.ed. México: Secretaría de Salud, 2000. p.2517-2518.
13. FARMACOPÉIA brasileira. 3.ed. São Paulo: Andrei, 1977, p.491-492.
14. FARMACOPÉIA brasileira. 4.ed. São Paulo: Atheneu, 1988. pt. 1. p.V.2.2.
15. FARMACOPÉIA brasileira. 4.ed. São Paulo: Atheneu, 2001, pt. 2, p.153-153.1.
16. FLORENCE, A.T., ATTWOOD, D. Princípios físicoquí micos em farmácia. São Paulo: Editora da Universidade de São Paulo, 2003. p.29-66.
17. GHOSH, L.K.; THAKUR, R. S.; SHARMA, N. C.; GHOSH, N. C.; GUPTA, B.K. Development and evaluation of an ideal formulation of glibenclamide by solid dispersion techniques. Boll. Chim. Farm., v.137, p.26-29, 1998.
18. HASSAN, M.A; NAJIB, N.M.; SULEIMAN, M.S. Characterization of glibenclamide glassy state. Int. J. Pharm. v.67, p.131-137, 1991.
19. JAPANESE Pharmacopoeia. 14.Ed. 2001. pt. 2. Disponível em: 〈http://jpdh.nihs.go.jp/jp14e〉 Acesso em: 10 jul. 2003.
20. KASIM, N.A.; WHITEHOUSE, M.; RAMACHANDRAN, C.; BERMEJO, M.; LENNERNAS, H.; HUSSAIN, JUNGINGER, H.E.; STAVCHANSKY, S.A; MIDHA, K.K.; SHAH, V.P.; AMIDON, G.L. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Molec. Pharm., v.1, p.85-96, 2004.
21. LEON y LEON, C.A.; THOMAS, M.A. Recent advances in the interpretation of mercury porosimetry data. GIT Lab. J. Int. Ed., v. 1, p.101-104, 1997.
22. LOWEL, S.; SHIELDS, J.E. Powder surface area and porosity. London: Chapman & Hall. 1991. 205 p.
23. MERCK index: an encyclopedia of chemicals, drugs and biologicals. 14. ed. Whitehouse Station: Merck Research Laboratories, 2006. p.773.
24. NERY, C.G.C.; PIANETTI, G.A.; PIRES, M.A.S.; MOREIRA-CAMPOS, L.M.; VIANNA-SOARES, C.D. Rev. Bras. Ciênc. Farm., v.43, n.3, p.413-419, 2007.
25. PANAGOPOULOU-KAPLANI, A.; MALAMATARIS, S. Preparation and characterisation of a new insoluble polymorphic form of glibenclamide. Int. J. Pharm. v.195, p.239-246, 2000,
26. SULEIMAN, M.S.; NAJIB, N.M. Isolation and physicochemical characterization of solid forms. Int. J. Pharm. v.50, p.103-109, 1989.
27. TAKLA, P.G. Glibenclamide. Anal. Profiles Drug Subst., v.10, p.338-355, 1981.
28. UNITED States Pharmacopeia. The National Formulary. 29.ed. Rockville: United States Pharmacopeial Convention, 2005. p.1010-1011.
29. YOSHIHASHI, Y.; KITANO, H.; YONEMOCHI, E.; TERADA, K. Quantitative correlation between initial dissolution rate and heat of fusion of drug substance. Int. J. Pharm., v.204, p.1-6, 2000.